- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04343885
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA)
UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Arun Azad, MBBS PhD FRACP
- Phone Number: +613 855 97165
- Email: Arun.Azad@petermac.org
Study Contact Backup
- Name: Michael Hofman, MBBS(Hons),FRACP,FAANMS,FICIS
- Phone Number: +613 855 96914
- Email: Michael.Hofman@petermac.org
Study Locations
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore
-
Sydney, New South Wales, Australia, 2050
- Chris O'Brien Lifehouse
-
Sydney, New South Wales, Australia, 2010
- St Vincent's Hospital Sydney
-
-
Queensland
-
Brisbane, Queensland, Australia, 4029
- Royal Brisbane and Women'S Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
-
Victoria
-
Malvern, Victoria, Australia, 3144
- Cabrini Hospital
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Centre
-
Melbourne, Victoria, Australia, 3084
- Austin Health
-
Prahran, Victoria, Australia, 3000
- Alfred Hospital
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Fiona Stanley Hospital
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for study registration:
- Patient has provided written informed consent
- Male aged 18 years or older at screening
- Prostate cancer diagnosed within 12 weeks of commencement of screening
- Histologically or cytologically confirmed adenocarcinoma of the prostate without significant neuroendocrine differentiation or small cell histology OR metastatic disease typical of prostate cancer (i.e. involving bone or pelvic lymph nodes or para-aortic lymph nodes) with a rising serum PSA
- Evidence of metastatic disease on CT and/or bone scan
- PSA > 10ng/ml prior to commencement of medical ADT or surgical orchidectomy
Adequate haematological, renal and hepatic functions as defined by:
- Absolute neutrophil count >1.5 x 109/L
- Platelet count >100 x 109/L
- Haemoglobin ≥ 90g/L (no red blood cell transfusion in 4 weeks prior to randomisation)
- Creatinine Clearance ≥ 40mL/min (Cockcroft-Gault formula)
- Total bilirubin < 1.5 x ULN (unless known or suspected Gilbert syndrome)
- Aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 2.0 x ULN (or ≤ 5.0 x ULN in the presence of liver metastases)
- Have a performance status of 0-2 on the ECOG Performance Scale (see Appendix 1)
- Life expectancy greater than 6 months with treatment
- Assessed by a medical oncologist as suitable for treatment with docetaxel
- Patients must agree to use an adequate method of contraception
- Willing and able to comply with all study requirements, including all treatments and required assessments including follow-up
Exclusion Criteria for Registration:
Any prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate cancer. The following exceptions are permitted:
- Up to 4 weeks of ADT with luteinising hormone releasing hormone agonists or antagonists or orchiectomy ± concurrent anti-androgens are permitted prior to commencement of screening. At investigator discretion, patients may start ADT at commencement of protocol therapy
- Up to one course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 14 days prior to registration
- Symptomatic cord compression, or clinical or imaging findings concerning for impending cord compression
- Central nervous system metastases
- Patients with Sjogren's syndrome
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
Prior diagnosis of another cancer that was:
- More than 3 years prior to current diagnosis with subsequent evidence of disease recurrence or clinical expectation of recurrence greater than 10%
- Within 3 years of current diagnosis with the exception of successfully treated basal cell or squamous cell skin carcinoma or adequately treated non-muscle invasive bladder cancer (Tis, Ta and low grade T1 tumours)
Inclusion Criteria for Randomisation:
- Significant PSMA avidity on 68Ga-PSMA PET/CT, defined after central review as a minimum uptake of SUVmax 15 at a site of disease
- High-volume metastatic disease on 68Ga-PSMA PET/CT defined as visceral metastases or ≥ 4 bone metastases with ≥ 1 outside the vertebral column and pelvis (extra-axial skeleton)
- Patient continues to meet all the inclusion criteria for registration
Exclusion Criteria for Randomisation:
- Major FDG-PET discordance defined as presence of FDG positive disease with minimal PSMA expression in multiple sites (>5) or in more than 50% of total disease volume
- All the exclusion criteria for registration continue to not apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 177Lu-PSMA+ Docetaxel
7.5 GBq (± 10%) 177Lu-PSMA every 6 weeks x 2 cycles.
Docetaxel 75 mg/m2 commencing 6 weeks later, every 3 weeks x 6 cycles
|
Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
Other Names:
Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
Other Names:
|
Other: Docetaxel (Control)
Docetaxel 75 mg/m2 every 3 weeks x 6 cycles
|
Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Undetectable prostate specific antigen (PSA) rate at 12 months after commencement of protocol therapy
Time Frame: Upto 32 months assuming 18 months to complete recruitment, a maximum of 1.6 months from consent to commencement of treatment for last patient and then 12 months from commencement of treatment for last patient.
|
Undetectable PSA is defined as PSA ≤ 0.2ng/ml at 12 months after protocol treatment commencement.
Patients who experience unequivocal radiographic (by conventional imaging modality) and/or clinical disease progression within 12 months of initiating protocol treatment will be considered as not having undetectable PSA at 12 months.
|
Upto 32 months assuming 18 months to complete recruitment, a maximum of 1.6 months from consent to commencement of treatment for last patient and then 12 months from commencement of treatment for last patient.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of 177Lu-PSMA followed by docetaxel compared to docetaxel alone
Time Frame: Through completion of treatment, maximum 26 months.
|
The type, grade and relationship to treatment of adverse events (AE) will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0
|
Through completion of treatment, maximum 26 months.
|
Time to development of castration resistance between treatment Arms
Time Frame: Through study completion, up until 2 years after the last patient commences treatment.
|
Castration resistance is defined as rising PSA and/or radiographic progression despite castrate levels of testosterone (≤ 50ng/dL or ≤ 1.73nmol/L).To be measured from the date of randomisation to the date of first evidence of castration resistance.
|
Through study completion, up until 2 years after the last patient commences treatment.
|
PSA-progression free survival (PSA-PFS) between treatment Arms
Time Frame: Through study completion, up until 2 years after the last patient commences treatment.
|
PSA progression is defined as a rise in PSA by more than 25% AND more than 2ng/mL above the nadir (lowest PSA point).
This needs to be confirmed by a repeat PSA performed at least 3 weeks later.
Early rises in PSA prior to 12 weeks will be disregarded in determining PSA progression.
To be measured from the date of randomisation to the first date of evidence of PSA progression or date of death due to any cause.
|
Through study completion, up until 2 years after the last patient commences treatment.
|
Radiographic-PFS (rPFS) between treatment Arms
Time Frame: Through study completion, up until 2 years after the last patient commences treatment.
|
Radiographic progression will be assessed by the investigator per RECIST1.1 for soft tissue and PCWG3 for bone lesions.
To be measured from randomisation to the first date of documented radiographic progression using conventional imaging or death due to any cause, whichever occurs first.
|
Through study completion, up until 2 years after the last patient commences treatment.
|
Early PSMA PET response between treatment Arms
Time Frame: Through completion of 3 months after treatment commencement for last patient, maximum 23 months.
|
PSMA PET response assessed 3 months after treatment commencement defined by central imaging review of 68Ga-PSMA PET CT images.
|
Through completion of 3 months after treatment commencement for last patient, maximum 23 months.
|
Describe and compare health-related QoL within 12 months of treatment commencement between treatment Arms
Time Frame: Through completion of 12 months after treatment commencement of last patient, maximum 32 months.
|
QoL will be assessed using the Functional Assessment of Cancer Therapy for Prostate Cancer (FACT-P) questionnaire. The primary endpoint for QoL is the area under the curve (AUC) of the trial outcome index (TOI). QoL will be assessed at baseline, 6 weeks, 3 months, 6 months, 9 months and 12 months and will be scored according to the respective manuals. |
Through completion of 12 months after treatment commencement of last patient, maximum 32 months.
|
Describe and compare pain within 12 months of treatment commencement between treatment Arms
Time Frame: Through completion of 12 months after treatment commencement of last patient, maximum 32 months.
|
Pain will be assessed using the Brief Pain Inventory - Short Form (BPI-SF). The primary endpoint for pain is the area under the curve (AUC) of the worst pain in 24h. Pain and QoL will be assessed at baseline, 6 weeks, 3 months, 6 months, 9 months and 12 months and will be scored according to the respective manuals. |
Through completion of 12 months after treatment commencement of last patient, maximum 32 months.
|
Overall survival (OS) between treatment Arms
Time Frame: Through study completion, up until 2 years after the last patient commences treatment.
|
OS is defined as the time from randomisation to the date of death due to any cause.
|
Through study completion, up until 2 years after the last patient commences treatment.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the correlation between PSMA and FDG PET/CT parameters and clinical outcomes
Time Frame: Through study completion, up until 2 years after the last patient commences treatment.
|
Prognostic and predictive value of PET-derived parameters including molecular tumour volume parameters (volume, SUVmax, SUVmean) and radiomics from PET, CT or bone scans using data-characterisation algorithms will be assessed.
|
Through study completion, up until 2 years after the last patient commences treatment.
|
Identify biomarkers potentially associated with clinical outcomes
Time Frame: Through study completion, up until 2 years after the last patient commences treatment.
|
Prognostic and predictive biomarkers associated with treatment outcome and response will be assessed.
This will include any of the following: i) circulating tumour DNA ± tumour tissue (DNA repair genes, tumour suppressor genes, androgen receptor); and ii) whole blood RNA (androgen receptor splice variants, TMPRSS2:ERG fusion).
|
Through study completion, up until 2 years after the last patient commences treatment.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Arun Azad, MBBS PhD FRACP, Peter MacCallum Cancer Centre, Australia
- Principal Investigator: Michael Hofman, MBBS(Hons),FRACP,FAANMS,FICIS, Peter MacCallum Cancer Centre, Australia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Radiopharmaceuticals
- Docetaxel
- 177Lu-PSMA-617
Other Study ID Numbers
- 19/195
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Hormone Naive Prostate Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Novartis PharmaceuticalsTerminatedProstate Cancer | Castrate Resistant Prostate Cancer | Chemotherapy Naive Prostate CancerUnited States
-
Turku University HospitalNot yet recruitingProstate Cancer | Localized Prostate Carcinoma | Intermediate Risk Prostate Cancer | Castration-Naive Prostate CancerFinland
-
Universitaire Ziekenhuizen KU LeuvenRecruitingProstate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis | Oligometastatic Disease | Hormone Sensitive Prostate CancerBelgium
-
DendreonCompletedHormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer MetastaticUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
Stanford UniversityNational Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Hormone-Resistant Prostate CancerUnited States
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
Cliniques universitaires Saint-Luc- Université...SanofiCompletedMetastatic Prostate Cancer | Hormone Resistant Prostate CancerBelgium, Luxembourg
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Hormone-Resistant Prostate CancerUnited States
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
Clinical Trials on 177Lu-PSMA-617
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Peter MacCallum Cancer Centre, AustraliaEndocyte; Movember Foundation; Medical Research Future Fund; E.J. Whitten Foundation...Active, not recruitingProstatic NeoplasmsAustralia
-
Centre Georges Francois LeclercNot yet recruitingPatients With Metastatic Castration-resistant Prostate Cancer
-
Novartis PharmaceuticalsRecruitingProstate CancerUnited States
-
University of California, San FranciscoMerck Sharp & Dohme LLC; Prostate Cancer FoundationRecruitingProstate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate CancerUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Peking Union Medical College HospitalRecruitingDiagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617Renal Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruitingAdenoid Cystic CarcinomaChina
-
Australian and New Zealand Urogenital and Prostate...Astellas Pharma Inc; Endocyte; Prostate Cancer Research Alliance; National Health...Active, not recruitingMetastatic Castration-Resistant Prostate CancerAustralia
-
Advanced Accelerator ApplicationsNo longer availableMetastatic Castration-resistant Prostate Cancer (mCRPC)